PfCLK3 inhibitor program (Keltic Pharma Therapeutics)

N/A

Report date: 2025/06/11 10:21:25
NME

Base Information

Drug NamePfCLK3 inhibitor program (Keltic Pharma Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionProtein kinase PfCLK3 inhibitors
TargetsProtein kinase PfCLK3
Therapy Area/IndicationsMalaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIreland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKeltic Pharma Therapeutics Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMalaria
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A